Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How do you choose between darolutamide and abiraterone when adding to docetaxel plus ADT in management of castrate sensitive high burden metastatic prostate cancer?
Related Questions
What are your top takeaways in GU Cancers from ESMO 2024?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
Is REZUM (water vapor thermotherapy for BPH) safe after EBRT?
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
In which patients are referring for focal gland therapy for localized prostate cancer?
